Clinical Trials Browser

Ovarian Neoplasms × Injections × Clear all

NCT03017131 2026-04-06

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07469202 2026-03-13

CYTALUX Dose Extension Study

Phase 4 Not yet recruiting

GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

NCT07042802 2026-03-06

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Phase 1/2 Recruiting

Ovarian Neoplasms

NCT04752826 2026-02-18

MK-3475-D20

Phase 1/2 Recruiting

DermatologicGynecologicLymphoid

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT06840002 2025-09-30

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Recruiting

Ovarian Neoplasms

NCT04778839 2025-08-06

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Phase 1 Recruiting

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms

NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Phase 1/2 Active not recruiting

15 enrolled 12 charts

DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT06828354 2025-03-24

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms, Recurrence

NCT02317705 2022-06-21

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

Phase 2 Completed

48 enrolled 10 charts

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Phase 3 Completed

140 enrolled 11 charts 2 FDA

Ovarian Neoplasms

NCT04489706 2020-07-28

Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation

Phase NA Unknown

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Phase 1 Completed

BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT03818282 2019-02-26

OC-01

Phase 2 Unknown

Ovarian Neoplasms

NCT00057720 2011-07-25

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms